Mammalian SWI/SNF (BAF) complex

The SWI/SNF complex, known as the BAF (BRG1/BRM-associated factor) complex in mammals is a chromatin remodeling complex with multiple subunits that regulate gene expression by altering chromatin accessibility and DNA access for transcription factors.[1][2][3] BAF complex remodels nucleosomes through ATP hydrolysis mediated by its catalytic subunits BRG1 (SMARCA4) or BRM (SMARCA2).

The BAF complex exists in three subtypes, canonical BAF (cBAF), polybromo-associated BAF (PBAF), and non-canonical BAF (ncBAF), each defined by unique subunit compositions that lead them to have specific biological functions.[4][5][6] Mutations, including the loss of function mutations, in specific subunits have been a driving factor in various human diseases, most notably cancer, making BAF complexes integral in current molecular biology and research pertaining to biomedicine.[7][8]

About 20% of patients with different forms of cancer had mutations in at least one BAF complex member.[9][10] In particular, these include breast cancers related to mutations in ARID1A/B, PBRM1, and ARID2,[11][10] endometriosis-associated ovarian cancers caused by mutations in ARID1A,[12][10] and renal medullary carcinomas characterized by loss of SMARCB1.[13][14] Additionally, both diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma are subtypes of non-Hodgkin lymphoma originating from germinal center B cells; while DLBCL is the most common, Burkitt lymphoma is the most aggressive and clinically significant.[15][16][10] Burkitt lymphoma, in particular, is frequently linked to mutations in ARID1A and SMARCA4.[10][17]

Structure and subunits

The BAF complex is composed of three main modules. Among these, the ATPase motor module is the driving force behind chromatin remodeling. This module uses the energy obtained from ATP hydrolysis to move nucleosomes along the DNA.[18][19] The core module, including ARID1A and SMARCC subunits, structures the complex and facilitates interactions with the other modules.[18][20] The Actin-Related Protein module, which connects these two modules, enhances the structural integrity of the complex and ensures proper transmission of mechanical forces within it.[21] Different combinations of the subunits that make up these modules determine the functional diversity of the complex, leading to the formation of subcomplexes such as cBAF, PBAF, and ncBAF (Table 1). Therefore, the structure of the BAF complex enables cell-specific genetic responses through specific dynamic interactions between modules and variability in subunit composition.[22][23][21]

  • cBAF: The cBAF complex, which is the most common among the others, plays a role in the initiation of gene expression. It functions primarily at enhancer regions, controlling developmental processes and playing a critical role in cell differentiation.[20][24]
  • PBAF: PBAF contributes to the maintenance of gene transcription. It is typically localized at active promoter regions and also functions as a tumor suppressor in certain contexts.[20]
  • ncBAF: Although it also acts at enhancer regions like cBAF, unlike the other two complex types, ncBAF has a distinct structure. It is known to regulate cell type-specific gene expression.[20][25] Moreover, the unique composition of the ncBAF complex (i.e. Bromodomain-containing protein 9 -BRD9- subunit) makes it an attractive target for drug development efforts.[26][27]

The three forms of the BAF complex (Figure 1) have different combinations of parts that show how each one works in a specific way. For example, the ncBAF includes SS18, GLTSCR1/1L, and BRD9; cBAF has ARID1A/B, DPF1/2/3, and SS18. SS18 is shared among these two complexes but not with PBAF. On the other hand, PBAF includes PHF10, ARID2, BRD7, and PBRM1, which are unique to it. Meanwhile, ACTL6, β-actin, BCL7A/B/C, SMARCA2/4, SMARCD1/2/3, SMARCB1, SMARCE1, and SMARCC1/2 are shared across all three complex types (Table 1).[5]

Table 1. Subunit compositions of mammalian BAF complexes

Subunit Type ncBAF cBAF PBAF
Shared ACTL6, β-actin, BCL7A/B/C, SMARCA2/4, SMARCD1/2/3, SMARCB1, SMARCE1, SMARCC1/2
Specific BRD9, GLTSCR1/1L, SS18 ARID1A/B, DPF1/2/3, SS18 PHF10, ARID2, BRD7, PBRM1

Biochemical mechanisms of BAF complex remodeling

Many remodeling enzymes utilize the energy derived from ATP hydrolysis to shift DNA along nucleosomes through its ATP-dependent DNA translocase activity. In BAF complexes, BGR1 and BRM are the catalytic subunits. After BRG1/BRM binds to the nucleosome through mechanisms such as twist diffusion[29] and loop recapture,[30] it applies a mechanical force to the DNA, loosening the interactions between the histone octamers and the DNA. In this way, the opened regions of DNA become accessible to various transcription factors, RNA polymerase II, and other regulatory proteins.[31][32][33] The subunits of this complex recognize specific histone modifications and DNA sequences: bromodomain-containing subunits (BRG1, BRM, PBRM1, BRD7/9) bind to acetylated histones,[34][35] while PHD fingers (e.g., DPF2/DPF3) specifically recognize acetylated H3 histone tails.[36] Additionally, the ARID1A/B and ARID2 subunits bind to AT-rich DNA regions.[17][37] What distinguishes the BAF complex from other chromatin remodeling complexes is its ability not only to shift nucleosomes but also to completely evict histone octamers when necessary.[33][38] Additionally, the BAF complex functions in balance with Polycomb complexes, which mediate gene repression through mechanisms such as H3K27 methylation. When BAF function is impaired while Polycomb activity remains intact, gene silencing persists, leading to the repression of tumor suppressor genes and potentially contributing to oncogenic outcomes.[39][40][41][42]

The BAF complex in cells plays roles in various processes such as cell differentiation, development, and maintenance of viability. Specifically, subunits like BRG1 and SMARCC1 maintain pluripotency,[43] subunit switching in neuronal cells enables neuronal differentiation,[44] and it regulates tissue-specific gene expression in muscle and heart.[45] In adult cells, the complex functions in DNA damage repair, cell cycle control, and preservation of cell identity.[41][46][47][48]

Roles in disease

The mammalian BAF complex is disrupted frequently in human disease, and mutations in the subunits of the BAF complex have been responsible for causing roughly 20% of all human tumors.[47][9] Subunits of the BAF complex like ARID1A, SMARCB1, SMARCA4, PBRM1, and ARID2 are considered to be tumor suppressors and are often affected by loss of function mutations across cancers.[49][50]

Because the BAF complex is modular, phenotypes in disease can indicate which subunit is altered.[6] Different subunits direct targeting and activity at enhancers, so mutations in different subunits have different methods, impact on tumorigenesis, and therapeutic vulnerabilities.[51] Through destabilizing the cBAF complex and the accessibility of enhancers, ARID1A, for instance, is mutated in nearly half of all ovarian clear-cell and endometrioid carcinomas and is associated with loss-of-function defects that occur early in the progression of malignant transformation of endometriosis.[52] The majority of ARID1A mutations are truncating, leading to the protein being lost; however, without ARID1A, cBAF shifts to using ARID1B, which has far less abundance at enhancers, all the while decreasing the accessibility of the chromatin.[53][54]

Beyond defects that target enhancers, the loss of structural subunits removes the platform that recruits BRG1/BRM onto the chromatin, diminishing remodeling at genes involved in checkpoint and differentiation.[55] Particularly, SMARCB1 is biallelically inactivated in nearly all malignant rhabdoid tumors, which demonstrates one of the first genetic links between loss of the BAF complex and severe pediatric cancers.[56][57] SMARCA4 loss of function can disable the very ATPase involved in remodeling in BAF and cause small cell carcinoma of the ovary, hypercalcemic type, while recurring as mutations in non-small cell lung cancers, where the restriction of nucleosome mobility can silence the existing tumor suppressor genes.[58]

Carcinogenic potential is not restricted to the cBAF complex, however, since over 40% of clear-cell renal carcinomas are characterized by PBRM1 deletions/truncations.[59] The loss of bromodomain in PBRM1 reduces the ability to recognize acetylated histones, causing a change in gene expression.[60] Although they are less frequent, ARID2 mutations, also disrupting PBAF-derived chromatin regulation, play a part in hepatocellular carcinoma development like that of hepatitis C through defectively recruiting chromatin remodelers to the tumor suppressors that restrain uncontrolled proliferation.[61][62]

Germline disruption of the BAF complex's chromatin-remodeling specific complexes is a central cause of Mendelian neurodevelopmental disease.[6] Clinically, ARID1B loss-of-function mutations are present in nearly two-thirds of cases of the Coffin–Siris spectrum, impeding proper intellectual development, language delays in expression, increased seizure susceptibility, and frequent midline neurological implications such as corpus-callosal defects.[63][64] Other subunits of the BAF complex, including ARID1A, SMARCB1, SMARCE1, and SMARCA4, can also cause Coffin–Siris–like phenotypes when mutated, underscoring the specific roles of this remodeling machinery in human neural development.[65] By contrast, Nicolaides–Baraitser syndrome is caused primarily by de novo missense variants in SMARCA2, which produce severe intellectual disability, distal-limb anomalies, and sparse hair.[66][67]

Role of ARID1A as tumor suppressor

ARID1A, as part of cBAF, possesses an essential tumor-suppressing activity that is frequently mutated in various human cancers, including in 46–57% of ovarian clear cell carcinomas and 30% of endometrioid carcinomas as well as in prostate, breast, pancreatic and more cancers.[68] One of ARID1A's several pivotal functions is its ability to direct cBAF to the enhancers, promoting oncogenesis through faulty genomic regulation.[69] Although ARID1A loss on its own has been shown as insufficient for tumorigenesis, it can induce ovarian adenocarcinomas when paired with PIK3CA activation, after having released IL-6 and activated NF-κB.[70][71] This cooperation between PI3K and ARID1A is prominent because PIK3CA supplies proliferation of cells and the loss of ARID1A changes the interactions between enhancers and inflammation within the cells, creating a feed-forward loop between IL-6, STAT3 and NFkB.[70] Namely, when ARID1A and PIK3CA are mutated, there is a promotion of IL-6 and activation of STAT3 because of the newly established inflammatory cytokine loop. In this signalling state, the interaction increases between the tumor and the environment surrounding it, recruiting pro-tumor myeloid cells.[70]

Because ARID1A loss with PIK3CA activation increases PI3K–AKT signalling, EZH2 blockade that restores the endogenous inhibitor PIK3IP1 provides a PIK3IP1-dependent vulnerability in ARID1A-mutant systems.[72] Through reactivating tumor suppressors like PIK3IP1, which can represent a potential therapeutic strategy due to its ability to limit PI3K–AKT signalling, EZH2 inhibition is able to target specifically cancer cells that are ARID1A-mutant tumors.[72]

ARID1A deficiency also limits interferon signaling, which is critical in the human immune response, as well as invasion of CD8+ T-cells.[73] Thus, the cell can pass through most immune checkpoints because the loss of ARID1A leads to closing antigen-related enhancers.[74] In prostate tumours, ARID1A deletion combines with loss of PTEN to increase the amount of tumor growth as well as PMN-MDSCs infiltration through continued NF-κB activation.[75] Inflammatory IKKβ signalling phosphorylates ARID1A, degrading the protein as well as silencing of A20 enhancer activity, which further boosts suppression from immune NF-κB, creating a feedback loop of NF-κB.[75]

SMARCB1 and rhabdoid tumors

In malignant rhabdoid tumors (MRTs) as well as atypical teratoid or rhabdoid tumors (ATRTs), SMARCB1 acts as a major tumor suppressor that shows bi-allelic inactivation in almost 95% of patients.[76] Without SMARCB1, the chromatin is repressed by Polycomb repressive complexes because SMARCB1 can mark specific genes for silencing and can even compact the chromatin further.[77] In contrast to most cases of cancer, invasive childhood neurological malignancies can arise through even the smallest change, sometimes with SMARCB1 as the sole driver event.[78] In fact, studies in mice have demonstrated that SMARCB1 functions as a tumor suppressor with two major pathways for destruction: if deleted heterozygously, there could be sporadic MRT development, whereas conditional homozygous loss leads to fast-spreading lymphomas, demonstrating that SMARCB1 by itself can be enough for tumorigenesis.[79] Rhabdoid tumorigenesis, however, can only happen in particular parts of development.[80] For instance, the loss of SMARCB1 affects embryonic progenitors, like neural stem cells or primordial germ cells, more than already differentiated cells, indicating the role of age in tissue tropism of RTs.[81] The activity of enhancers requires SMARCB1, and, as evidence, its loss can stifle the ability of genes to allow cells to differentiate.[76] Consequently, rhabdoid tumor cells are specifically vulnerable to the ratios of other SWI/SNF proteins. For instance, rhabdoid tumors without SMARCB1 specifically require BRD9, with BRD9 inhibition leading to cytotoxicity within these cells.[76] By contrast, the loss of SMARCB1 lowers the ability of the BAF complex to antagonize Polycomb repressive complexes, expanding the domain of H3K27me3 domains by allowing PRC2 to spread H3K27me3 at promoters where there are differentiation genes.[82] This creates a therapeutic vulnerability to EZH2 inhibition, a strategy that is supported by clinical evaluation with agents such as tazemetostat.[83][84] Although rare cases can include the loss of SMARCA4 rather than SMARCB1, the resulting defects in chromatin remodeling are very similar, indicating potentially shared therapeutic targets.[85][86]

SMARCA4 and cancer

SMARCA4, otherwise called BRG1, is one of the most integral tumor suppressors in the BAF complex, and its loss can lead to mechanistically different but functionally similar types of aggressive malignancies.[87] In hypercalcemic ovarian small cell carcinoma, biallelic mutations of SMARCA4 gene, which leads to the loss of BRG1, are extremely widespread, as shown in ovary small cell carcinoma, where 94% of the cases have SMARCA4 mutation.[88] In fact, identification of the genetic status of SMARCA4 is one of the criteria/the main criterion for confirming the disease.[89] Moreover, blocking a second, compensatory pathway that the cells rely on after the first copy of the gene is lost stands out as a therapeutic possibility.[87] When SMARCA4 is lost, the ATPase activity of the BAF complex is compromised, with only SMARCA2 compensating as the ATPase subunit in SMARCA4-dependent cells, resulting in altered enhancers and promoter accessibility, so transcription factors that would otherwise have access to DNA no longer reach their targets.[90] In non-small cell lung cancer, SMARCA4 mutations are present in about 5–10% of tumors, especially in those with undifferentiated or rhabdoid phenotype.[91] At a more cellular level, BRG1 loss disrupts chromatin accessibility that cells obtain from SWI/SNF, reducing DNA repair through p53 and BRCA1, as well as activating previously inactivated oncogenic MYC programs.[92][93][94] Activation of MYC programs accelerates the cell cycle, increasing transcriptional demand, which promotes growth but also elevates replication stress. These changes collectively destabilize the genome and lead to dedifferentiation through loss of H3K27 acetylation.[95][96] These mutations may lead to therapeutic susceptibilities, where SMARCA4-deficient cells face replication stress as well as chromatin compaction, making them highly sensitive to ATR inhibitors.[97] The said replication stress can cause DNA breaks and chromosome instability that drive tumor initiation.

Therapeutic strategies

Mutations of the SWI/SNF complex have provided the initial push for finding therapeutic measures to target cancers where ARID1A is mutated.[98] Common ARID1A loss-of-function cancers allow for specific properties that are being examined to understand more about the role of mutations in subunits of SWI/SNF in the proliferation of cancer cells.[99] Epigenetic therapy is one of the advancements made in this matter, where it was found that cancer cells lacking ARID1A can die when EZH2 is inhibited.[100] In particular, ARID1A-mutant ovarian clear cell carcinomas show dramatic regression when there is the inhibition of EZH2.[72] ARID1A-loss malignancies are similarly very reliant on ATR-mediated DNA damage checkpoints.[101] As such, inhibition of the ATR kinase acts specifically to induce DNA damage, premature mitosis, and cell death of ARID1A-loss models, which has prompted clinical studies.[102] ARID1A loss decreases homologous recombination repair, which repairs harmful DNA breaks, so the cells are acutely susceptible to inhibition of PARP, a protein found in the cell nucleus that can detect said DNA damage.[103][104]

Besides impacting the cell cycle alongside DNA repair tracks, ARID1A inactivation produces metabolic instabilities as well.[105] ARID1A-mutant tumors can become addicted to glutamine as a side-product of glycolysis down-regulation in their cells as well as enhanced glutaminase dependence. Therefore, inhibition of GLS1, the enzyme that converts glutamine to glutamate, causes metabolic collapse.[106] Other BAF complex subunits are also being used for research into cancer therapy. In fact, loss of SMARCB1, as seen in cancerous rhabdoid tumors and epithelioid sarcoma, causes early dependence on EZH2 activity.[107] Similarly, inhibition of EZH2 by the EZH2 inhibitor tazemetostat has shown clinical activity as an approved treatment of SMARCB1-deficient sarcomas.[108] Random mutations of the PBAF sub-complex also offer hints at immune therapy since mutations of the PBRM1 gene in renal cell carcinomas are related to improved response to PD-1 blockade, which uses inhibitors that target PD-1 protein in T cells, allowing the immune system to attack the said cancer cells.[109]

History

SWI/SNF complexes were discovered in the 1980s in yeast, Saccharomyces cerevisiae.[110][111] The "SWI" (Switch) and "SNF" (Sucrose Non-Fermenting) genes were named for their roles in mating type switching and sucrose metabolism, respectively. These genes' crucial involvement in chromatin remodeling was revealed when their loss of function interfered with related transcriptional processes.[112][113][114] In the late 1980s, complexes analogous to the yeast SWI/SNF were also identified in the fruit fly Drosophila melanogaster, based on their genetic antagonism to Polycomb-mediated gene repression.[115][116] The central ATPase subunit of these complexes is encoded by the brahma (brm) gene, from which the name BAP (Brahma-associated proteins) complex is derived. In addition to BAP, D. melanogaster has a second BRM-containing complex known as PBAP (Polybromo-associated BAP). Although both complexes function to counteract Polycomb silencing, they exhibit distinct roles in different biological processes.[117][118][119]

The identification of SWI/SNF-like complexes in mammalian cells became possible shortly after the molecular cloning of genes homologous to the yeast SWI2/SNF2 genes. Two ATPase subunits of the SNF2 family, BRG1 (Brahma-related gene 1) and hBRM (human Brahma), which use ATP to remodel nucleosomes, were identified in the early 1990s.[120][121] These findings demonstrated that SWI/SNF complexes are evolutionarily conserved in mammals. Subsequent biochemical purification studies revealed the existence of two distinct complexes in mammalian cells containing either BRG1 or BRM, each assembling with different and partially overlapping subunits. These complexes are collectively referred to as BAF. Compared to the yeast SWI/SNF complex, BAF complexes exhibit much greater structural and functional diversity (Table 2). This diversity allows them to regulate specific transcriptional processes across various cell types and developmental stages. To improve upon the comparison between different species that is given from this diversity, the SWI/SNF Infobase was developed as a comprehensive database containing subunit-specific protein and nucleic acid sequence information from approximately 20 different organisms.[122] Over time, it became evident that these complexes can change significantly, especially in development and differentiation. For example, during neural development, a transition occurs from the neural progenitor BAF complex to the neuronal BAF complex, involving subunit-level changes such as the replacement of BAF53A (ACTL6A) with BAF53B (ACTL6B).[43][44] In recent years, high-throughput sequencing and genome analyses have further revealed that BAF complexes have tumor suppressor roles. Notably, genes encoding several subunits, including ARID1A, SMARCB1, PBRM1, and SMARCA4 (which encodes BRG1), have been found to be frequently mutated in various human cancers.[54][50][47][17]

Table 2. Cross-species organization of SWI/SNF complexes

Feature Yeast (S. cerevisiae) Drosophila melanogaster Mammals
ATPase subunit Snf2 Brahma (BRM) BRG1 (SMARCA4), BRM (SMARCA2)
Number of subunits ~11 ~12-14 15-17
Complex diversity One main complex Two complexes (BAP and PBAP) Three complexes (cBAF, PBAF, ncBAF)
Evolutionary conservation Basic structural conservation Moderate similarity High complexity and specialization
Functional divergence Gene expression Developmental gene regulation Differentiation, cancer, DNA repair

References

  1. ^ Gourisankar, Sai; Krokhotin, Andrey; Wenderski, Wendy; Crabtree, Gerald R. (May 2024). "Context-specific functions of chromatin remodellers in development and disease". Nature Reviews Genetics. 25 (5): 340–361. doi:10.1038/s41576-023-00666-x. PMC 11867214. PMID 38001317.
  2. ^ Barisic, Darko; Stadler, Michael B.; Iurlaro, Mario; Schübeler, Dirk (May 2019). "Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factors". Nature. 569 (7754): 136–140. Bibcode:2019Natur.569..136B. doi:10.1038/s41586-019-1115-5. PMC 6522387. PMID 30996347.
  3. ^ Kadoch, Cigall; Crabtree, Gerald R. (5 June 2015). "Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics". Science Advances. 1 (5) e1500447. Bibcode:2015SciA....1E0447K. doi:10.1126/sciadv.1500447. PMC 4640607. PMID 26601204.
  4. ^ Gatchalian, Jovylyn; Malik, Shivani; Ho, Josephine; Lee, Dong-Sung; Kelso, Timothy W. R.; Shokhirev, Maxim N.; Dixon, Jesse R.; Hargreaves, Diana C. (3 December 2018). "A non-canonical BRD9-containing BAF chromatin remodeling complex regulates naive pluripotency in mouse embryonic stem cells". Nature Communications. 9 (1) 5139. Bibcode:2018NatCo...9.5139G. doi:10.1038/s41467-018-07528-9. PMC 6277444. PMID 30510198.
  5. ^ a b Michel, Brittany C.; D'Avino, Andrew R.; Cassel, Seth H.; Mashtalir, Nazar; McKenzie, Zachary M.; McBride, Matthew J.; Valencia, Alfredo M.; Zhou, Qianhe; Bocker, Michael; Soares, Luis M. M.; Pan, Joshua; Remillard, David I.; Lareau, Caleb A.; Zullow, Hayley J.; Fortoul, Nora; Gray, Nathanael S.; Bradner, James E.; Chan, Ho Man; Kadoch, Cigall (December 2018). "A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation". Nature Cell Biology. 20 (12): 1410–1420. doi:10.1038/s41556-018-0221-1. PMC 6698386. PMID 30397315.
  6. ^ a b c Alfert, Amelie; Moreno, Natalia; Kerl, Kornelius (December 2019). "The BAF complex in development and disease". Epigenetics & Chromatin. 12 (1) 19. doi:10.1186/s13072-019-0264-y. PMC 6427853. PMID 30898143.
  7. ^ Nguyen, Vinh The; Tessema, Mathewos; Weissman, Bernard Ellis (2023). "The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer". Epigenetics in Oncology. Cancer Treatment and Research. Vol. 190. pp. 211–244. doi:10.1007/978-3-031-45654-1_7. ISBN 978-3-031-45653-4. PMID 38113003.
  8. ^ Arnaud, Ophelie; Le Loarer, François; Tirode, Franck (April 2018). "BAFfling pathologies: Alterations of BAF complexes in cancer". Cancer Letters. 419: 266–279. doi:10.1016/j.canlet.2018.01.046. PMID 29374542.
  9. ^ a b Helming, Katherine C.; Wang, Xiaofeng; Roberts, Charles W. M. (September 8, 2014). "Vulnerabilities of Mutant SWI/SNF Complexes in Cancer". Cancer Cell. 26 (3): 309–317. doi:10.1016/j.ccr.2014.07.018. PMC 4159614. PMID 25203320.
  10. ^ a b c d e Wang, Xiaofeng; Haswell, Jeffrey R.; Roberts, Charles W.M. (1 January 2014). "Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer—Mechanisms and Potential Therapeutic Insights". Clinical Cancer Research. 20 (1): 21–27. doi:10.1158/1078-0432.CCR-13-0280. PMC 3947303. PMID 24122795.
  11. ^ Li, Kexuan; Wang, Baocai; Hu, Haolin (17 February 2024). "Research progress of SWI/SNF complex in breast cancer". Epigenetics & Chromatin. 17 (1) 4. doi:10.1186/s13072-024-00531-z. PMC 10873968. PMID 38365747.
  12. ^ Fukumoto, Takeshi; Magno, Elizabeth; Zhang, Rugang (1 December 2018). "SWI/SNF Complexes in Ovarian Cancer: Mechanistic Insights and Therapeutic Implications". Molecular Cancer Research. 16 (12): 1819–1825. doi:10.1158/1541-7786.MCR-18-0368. PMC 6279546. PMID 30037854.
  13. ^ Msaouel, Pavlos; Malouf, Gabriel G.; Su, Xiaoping; Yao, Hui; Tripathi, Durga N.; Soeung, Melinda; Gao, Jianjun; Rao, Priya; Coarfa, Cristian; Creighton, Chad J.; Bertocchio, Jean-Philippe; Kunnimalaiyaan, Selvi; Multani, Asha S.; Blando, Jorge; He, Rong; Shapiro, Daniel D.; Perelli, Luigi; Srinivasan, Sanjana; Carbone, Federica; Pilié, Patrick G.; Karki, Menuka; Seervai, Riyad N.H.; Vokshi, Bujamin H.; Lopez-Terrada, Dolores; Cheng, Emily H.; Tang, Ximing; Lu, Wei; Wistuba, Ignacio I.; Thompson, Timothy C.; Davidson, Irwin; Giuliani, Virginia; Schlacher, Katharina; Carugo, Alessandro; Heffernan, Timothy P.; Sharma, Padmanee; Karam, Jose A.; Wood, Christopher G.; Walker, Cheryl L.; Genovese, Giannicola; Tannir, Nizar M. (May 2020). "Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma". Cancer Cell. 37 (5): 720–734.e13. doi:10.1016/j.ccell.2020.04.002. PMC 7288373. PMID 32359397.
  14. ^ Jia, Liwei; Carlo, Maria I.; Khan, Hina; Nanjangud, Gouri J.; Rana, Satshil; Cimera, Robert; Zhang, Yanming; Hakimi, A.Ari; Verma, Amit K.; Al-Ahmadie, Hikmat A.; Fine, Samson W.; Gopalan, Anuradha; Sirintrapun, S.Joseph; Tickoo, Satish K.; Reuter, Victor E.; Gartrell, Benjamin A.; Chen, Ying-Bei (September 2019). "Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases". Modern Pathology. 32 (9): 1329–1343. doi:10.1038/s41379-019-0273-1. PMC 6731129. PMID 30980040.
  15. ^ Caro, Pilar; Kishan, Amar U.; Norberg, Erik; Stanley, Illana A.; Chapuy, Bjoern; Ficarro, Scott B.; Polak, Klaudia; Tondera, Daniel; Gounarides, John; Yin, Hong; Zhou, Feng; Green, Michael R.; Chen, Linfeng; Monti, Stefano; Marto, Jarrod A.; Shipp, Margaret A.; Danial, Nika N. (October 16, 2012). "Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B Cell Lymphoma". Cancer Cell. 22 (4): 547–560. doi:10.1016/j.ccr.2012.08.014. PMC 3479446. PMID 23079663.
  16. ^ Chuang, Shih-Sung; Ye, Hongtao; Du, Ming-Qing; Lu, Chin-Li; Dogan, Ahmet; Hsieh, Pin-Pen; Huang, Wan-Ting; Jung, Yun-Chih (October 2007). "Histopathology and Immunohistochemistry in Distinguishing Burkitt Lymphoma From Diffuse Large B-Cell Lymphoma With Very High Proliferation Index and With or Without a Starry-Sky Pattern: A Comparative Study With EBER and FISH". American Journal of Clinical Pathology. 128 (4): 558–564. doi:10.1309/EQJR3D3V0CCQGP04. PMID 17875505.
  17. ^ a b c Barisic, Darko; Chin, Christopher R.; Meydan, Cem; Teater, Matt; Tsialta, Ioanna; Mlynarczyk, Coraline; Chadburn, Amy; Wang, Xuehai; Sarkozy, Margot; Xia, Min; Carson, Sandra E.; Raggiri, Santo; Debek, Sonia; Pelzer, Benedikt; Durmaz, Ceyda; Deng, Qing; Lakra, Priya; Rivas, Martin; Steidl, Christian; Scott, David W.; Weng, Andrew P.; Mason, Christopher E.; Green, Michael R.; Melnick, Ari (April 2024). "ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis". Cancer Cell. 42 (4): 583–604.e11. doi:10.1016/j.ccell.2024.02.010. PMC 11407687. PMID 38458187.
  18. ^ a b He, Shuang; Wu, Zihan; Tian, Yuan; Yu, Zishuo; Yu, Jiali; Wang, Xinxin; Li, Jie; Liu, Bijun; Xu, Yanhui (21 February 2020). "Structure of nucleosome-bound human BAF complex". Science. 367 (6480): 875–881. Bibcode:2020Sci...367..875H. doi:10.1126/science.aaz9761. PMID 32001526.
  19. ^ Grossi, Elena; Nguyen, Christie B.; Carcamo, Saul; Kirigin Callaú, Valentina; Moran, Shannon; Filipescu, Dan; Tagore, Somnath; Firestone, Tessa M.; Keogh, Michael-Christopher; Sun, Lu; Izar, Benjamin; Hasson, Dan; Bernstein, Emily (2025). "The SWI/SNF PBAF complex facilitates REST occupancy at repressive chromatin". Molecular Cell. 85 (9): 1714–1729.e7. bioRxiv 10.1101/2024.08.23.609212. doi:10.1016/j.molcel.2025.03.026. PMC 12048221. PMID 40252649.
  20. ^ a b c d Mashtalir, Nazar; Dao, Hai T.; Sankar, Akshay; Liu, Hengyuan; Corin, Aaron J.; Bagert, John D.; Ge, Eva J.; D'Avino, Andrew R.; Filipovski, Martin; Michel, Brittany C.; Dann, Geoffrey P.; Muir, Tom W.; Kadoch, Cigall (16 July 2021). "Chromatin landscape signals differentially dictate the activities of mSWI/SNF family complexes". Science. 373 (6552): 306–315. Bibcode:2021Sci...373..306M. doi:10.1126/science.abf8705. PMC 8390793. PMID 34437148.
  21. ^ a b Mashtalir, Nazar; Suzuki, Hiroshi; Farrell, Daniel P.; Sankar, Akshay; Luo, Jie; Filipovski, Martin; D'Avino, Andrew R.; St. Pierre, Roodolph; Valencia, Alfredo M.; Onikubo, Takashi; Roeder, Robert G.; Han, Yan; He, Yuan; Ranish, Jeffrey A.; DiMaio, Frank; Walz, Thomas; Kadoch, Cigall (October 2020). "A Structural Model of the Endogenous Human BAF Complex Informs Disease Mechanisms". Cell. 183 (3): 802–817.e24. doi:10.1016/j.cell.2020.09.051. PMC 7717177. PMID 33053319.
  22. ^ Yuan, Junjie; Chen, Kangjing; Zhang, Wenbo; Chen, Zhucheng (5 May 2022). "Structure of human chromatin-remodelling PBAF complex bound to a nucleosome". Nature. 605 (7908): 166–171. Bibcode:2022Natur.605..166Y. doi:10.1038/s41586-022-04658-5. PMID 35477757.
  23. ^ Eustermann, Sebastian; Patel, Avinash B.; Hopfner, Karl-Peter; He, Yuan; Korber, Philipp (April 2024). "Energy-driven genome regulation by ATP-dependent chromatin remodellers". Nature Reviews Molecular Cell Biology. 25 (4): 309–332. doi:10.1038/s41580-023-00683-y. PMC 12303036. PMID 38081975.
  24. ^ Nocente, Marina C.; Mesihovic Karamitsos, Anida; Drouineau, Emilie; Soleil, Manon; Albawardi, Waad; Dulary, Cécile; Ribierre, Florence; Picaud, Hélène; Alibert, Olivier; Acker, Joël; Kervella, Marie; Aude, Jean-Christophe; Gilbert, Nick; Ochsenbein, Françoise; Chantalat, Sophie; Gérard, Matthieu (November 2024). "cBAF generates subnucleosomes that expand OCT4 binding and function beyond DNA motifs at enhancers". Nature Structural & Molecular Biology. 31 (11): 1756–1768. doi:10.1038/s41594-024-01344-0. PMID 38956169.
  25. ^ Marina-Zárate, Ester; Rodríguez-Ronchel, Ana; Gómez, Manuel J.; Sánchez-Cabo, Fátima; Ramiro, Almudena R. (March 2023). "Low-affinity CTCF binding drives transcriptional regulation whereas high-affinity binding encompasses architectural functions". iScience. 26 (3) 106106. Bibcode:2023iSci...26j6106M. doi:10.1016/j.isci.2023.106106. PMC 9958374. PMID 36852270.
  26. ^ Rej, Rohan Kalyan; Allu, Srinivasa Rao; Roy, Joyeeta; Acharyya, Ranjan Kumar; Kiran, I. N. Chaithanya; Addepalli, Yesu; Dhamodharan, V. (12 April 2024). "Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs". Pharmaceuticals. 17 (4): 494. doi:10.3390/ph17040494. PMC 11054475. PMID 38675453.
  27. ^ Dreier, Megan R.; Walia, Jasmine; de la Serna, Ivana L. (4 February 2024). "Targeting SWI/SNF Complexes in Cancer: Pharmacological Approaches and Implications". Epigenomes. 8 (1): 7. doi:10.3390/epigenomes8010007. PMC 10885108. PMID 38390898.
  28. ^ Wanior, M (2021). "Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy". Oncogene. 40 (21): 3637–3654. doi:10.1038/s41388-021-01781-x. PMC 8154588. PMID 33941852.
  29. ^ Liu, Ning; Balliano, Angela; Hayes, Jeffrey J. (24 January 2011). "Mechanism(s) of SWI/SNF-Induced Nucleosome Mobilization". ChemBioChem. 12 (2): 196–204. doi:10.1002/cbic.201000455. PMC 3787519. PMID 21243709.
  30. ^ Zhang, Yongli; Smith, Corey L.; Saha, Anjanabha; Grill, Stephan W.; Mihardja, Shirley; Smith, Steven B.; Cairns, Bradley R.; Peterson, Craig L.; Bustamante, Carlos (November 2006). "DNA Translocation and Loop Formation Mechanism of Chromatin Remodeling by SWI/SNF and RSC". Molecular Cell. 24 (4): 559–568. doi:10.1016/j.molcel.2006.10.025. PMC 9034902. PMID 17188033.
  31. ^ Hao, Fengxiang; Zhang, Ying; Hou, Jiayi; Zhao, Bin (23 April 2025). "Chromatin remodeling and cancer: the critical influence of the SWI/SNF complex". Epigenetics & Chromatin. 18 (1) 22. doi:10.1186/s13072-025-00590-w. PMC 12016160. PMID 40269969.
  32. ^ Eberharter, Anton; Becker, Peter B. (1 August 2004). "ATP-dependent nucleosome remodelling: factors and functions". Journal of Cell Science. 117 (17): 3707–3711. doi:10.1242/jcs.01175. PMID 15286171.
  33. ^ a b Brahma, Sandipan; Henikoff, Steven (January 2024). "The BAF chromatin remodeler synergizes with RNA polymerase II and transcription factors to evict nucleosomes". Nature Genetics. 56 (1): 100–111. doi:10.1038/s41588-023-01603-8. PMC 10786724. PMID 38049663.
  34. ^ Wang, Li; Yu, Jiali; Yu, Zishuo; Wang, Qianmin; Li, Wanjun; Ren, Yulei; Chen, Zhenguo; He, Shuang; Xu, Yanhui (10 December 2022). "Structure of nucleosome-bound human PBAF complex". Nature Communications. 13 (1) 7644. Bibcode:2022NatCo..13.7644W. doi:10.1038/s41467-022-34859-5. PMC 9741621. PMID 36496390.
  35. ^ Liao, Lili; Alicea-Velázquez, Nilda L.; Langbein, Lauren; Niu, Xiaohua; Cai, Weijia; Cho, Eun-Ah; Zhang, Meiling; Greer, Celeste B.; Yan, Qin; Cosgrove, Michael S.; Yang, Haifeng (April 2019). "High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM 1". Molecular Oncology. 13 (4): 811–828. doi:10.1002/1878-0261.12434. PMC 6441893. PMID 30585695.
  36. ^ Matusyama, Reiko; Takada, Ichiro; Yokoyama, Atsushi; Fujiyma-Nakamura, Sally; Tsuji, Naoya; Kitagawa, Hirochika; Fujiki, Ryoji; Kim, Misun; Kouza-Fujita, Madoka; Yano, Tetsu; Kato, Shigeaki (February 2015). "Retraction: Double PHD fingers protein DPF2 recognizes acetylated histones and suppresses the function of estrogen-related receptor α through histone deacetylase 1". Journal of Biological Chemistry. 290 (8): 4816. doi:10.1074/jbc.A109.077024. PMC 4335221. PMID 25713408.
  37. ^ Patil, Ajinkya; Strom, Amy R.; Paulo, Joao A.; Collings, Clayton K.; Ruff, Kiersten M.; Shinn, Min Kyung; Sankar, Akshay; Cervantes, Kasey S.; Wauer, Tobias; St. Laurent, Jessica D.; Xu, Grace; Becker, Lindsay A.; Gygi, Steven P.; Pappu, Rohit V.; Brangwynne, Clifford P.; Kadoch, Cigall (October 2023). "A disordered region controls cBAF activity via condensation and partner recruitment". Cell. 186 (22): 4936–4955.e26. doi:10.1016/j.cell.2023.08.032. PMC 10792396. PMID 37788668.
  38. ^ Rawal, Yashpal; Chereji, Răzvan V.; Qiu, Hongfang; Ananthakrishnan, Sudha; Govind, Chhabi K.; Clark, David J.; Hinnebusch, Alan G. (1 May 2018). "SWI/SNF and RSC cooperate to reposition and evict promoter nucleosomes at highly expressed genes in yeast". Genes & Development. 32 (9–10): 695–710. doi:10.1101/gad.312850.118. PMC 6004078. PMID 29785963.
  39. ^ Mathur, Radhika; Roberts, Charles W.M. (4 March 2018). "SWI/SNF (BAF) Complexes: Guardians of the Epigenome". Annual Review of Cancer Biology. 2 (1): 413–427. doi:10.1146/annurev-cancerbio-030617-050151.
  40. ^ Weber, Christopher M.; Hafner, Antonina; Kirkland, Jacob G.; Braun, Simon M. G.; Stanton, Benjamin Z.; Boettiger, Alistair N.; Crabtree, Gerald R. (June 2021). "mSWI/SNF promotes Polycomb repression both directly and through genome-wide redistribution". Nature Structural & Molecular Biology. 28 (6): 501–511. doi:10.1038/s41594-021-00604-7. PMC 8504423. PMID 34117481.
  41. ^ a b Panditharatna, Eshini; Marques, Joana G.; Wang, Tingjian; Trissal, Maria C.; Liu, Ilon; Jiang, Li; Beck, Alexander; Groves, Andrew; Dharia, Neekesh V.; Li, Deyao; Hoffman, Samantha E.; Kugener, Guillaume; Shaw, McKenzie L.; Mire, Hafsa M.; Hack, Olivia A.; Dempster, Joshua M.; Lareau, Caleb; Dai, Lingling; Sigua, Logan H.; Quezada, Michael A.; Stanton, Ann-Catherine J.; Wyatt, Meghan; Kalani, Zohra; Goodale, Amy; Vazquez, Francisca; Piccioni, Federica; Doench, John G.; Root, David E.; Anastas, Jamie N.; Jones, Kristen L.; Conway, Amy Saur; Stopka, Sylwia; Regan, Michael S.; Liang, Yu; Seo, Hyuk-Soo; Song, Kijun; Bashyal, Puspalata; Jerome, William P.; Mathewson, Nathan D.; Dhe-Paganon, Sirano; Suvà, Mario L.; Carcaboso, Angel M.; Lavarino, Cinzia; Mora, Jaume; Nguyen, Quang-De; Ligon, Keith L.; Shi, Yang; Agnihotri, Sameer; Agar, Nathalie Y.R.; Stegmaier, Kimberly; Stiles, Charles D.; Monje, Michelle; Golub, Todd R.; Qi, Jun; Filbin, Mariella G. (11 November 2022). "BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma". Cancer Discovery. 12 (12): OF1 – OF26. doi:10.1158/2159-8290.CD-21-1491. PMC 9716260. PMID 36305736.
  42. ^ Kadoch, Cigall; Williams, Robert T; Calarco, Joseph P; Miller, Erik L; Weber, Christopher M; Braun, Simon M G; Pulice, John L; Chory, Emma J; Crabtree, Gerald R (February 2017). "Dynamics of BAF–Polycomb complex opposition on heterochromatin in normal and oncogenic states". Nature Genetics. 49 (2): 213–222. doi:10.1038/ng.3734. PMC 5285326. PMID 27941796.
  43. ^ a b Ho, Lena; Jothi, Raja; Ronan, Jehnna L.; Cui, Kairong; Zhao, Keji; Crabtree, Gerald R. (31 March 2009). "An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network". Proceedings of the National Academy of Sciences. 106 (13): 5187–5191. Bibcode:2009PNAS..106.5187H. doi:10.1073/pnas.0812888106. PMC 2654397. PMID 19279218.
  44. ^ a b Lessard, Julie; Wu, Jiang I.; Ranish, Jeffrey A.; Wan, Mimi; Winslow, Monte M.; Staahl, Brett T.; Wu, Hai; Aebersold, Ruedi; Graef, Isabella A.; Crabtree, Gerald R. (July 2007). "An Essential Switch in Subunit Composition of a Chromatin Remodeling Complex during Neural Development". Neuron. 55 (2): 201–215. doi:10.1016/j.neuron.2007.06.019. PMC 2674110. PMID 17640523.
  45. ^ Ma, Zhaoru; Tan, Shuping; Lu, Renhong; Chen, Peixin; Hu, Yukun; Yang, Tenghui; Wu, Hao; Zhu, Zhexin; Guo, Jiayi; Chen, Xi; Yang, Jian; Zhang, Wensheng; Ye, Ying (February 2025). "Interplay of chromatin remodeling BAF complexes in mouse embryonic and epiblast stem cell conversion and maintenance". Journal of Biological Chemistry. 301 (2) 108140. Bibcode:2025JBiCh.301j8140M. doi:10.1016/j.jbc.2024.108140. PMC 11791114. PMID 39730061.
  46. ^ Dunaief, Joshua L.; Strober, Bruce E.; Guha, Sushovan; Khavari, Paul A.; Ålin, Kimona; Luban, Jeremy; Begemann, Martin; Crabtree, Gerald R.; Goff, Stephen P. (October 1994). "The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest". Cell. 79 (1): 119–130. doi:10.1016/0092-8674(94)90405-7. PMID 7923370.
  47. ^ a b c Kadoch, Cigall; Hargreaves, Diana C; Hodges, Courtney; Elias, Laura; Ho, Lena; Ranish, Jeff; Crabtree, Gerald R (June 2013). "Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy". Nature Genetics. 45 (6): 592–601. doi:10.1038/ng.2628. PMC 3667980. PMID 23644491.
  48. ^ Ho, Lena; Crabtree, Gerald R. (January 2010). "Chromatin remodelling during development". Nature. 463 (7280): 474–484. Bibcode:2010Natur.463..474H. doi:10.1038/nature08911. PMC 3060774. PMID 20110991.
  49. ^ Schick, Sandra; Rendeiro, André F.; Runggatscher, Kathrin; Ringler, Anna; Boidol, Bernd; Hinkel, Melanie; Májek, Peter; Vulliard, Loan; Penz, Thomas; Parapatics, Katja; Schmidl, Christian; Menche, Jörg; Boehmelt, Guido; Petronczki, Mark; Müller, André C.; Bock, Christoph; Kubicek, Stefan (September 2019). "Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers". Nature Genetics. 51 (9): 1399–1410. doi:10.1038/s41588-019-0477-9. PMC 6952272. PMID 31427792.
  50. ^ a b Shain, A. Hunter; Pollack, Jonathan R. (23 January 2013). "The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers". PLOS ONE. 8 (1) e55119. Bibcode:2013PLoSO...855119S. doi:10.1371/journal.pone.0055119. PMC 3552954. PMID 23355908.
  51. ^ Hu, Zhenhua; Tee, Wee-Wei (30 April 2017). "Enhancers and chromatin structures: regulatory hubs in gene expression and diseases". Bioscience Reports. 37 (2) BSR20160183. doi:10.1042/BSR20160183. PMC 5408663. PMID 28351896.
  52. ^ Wiegand, Kimberly C.; Shah, Sohrab P.; Al-Agha, Osama M.; Zhao, Yongjun; Tse, Kane; Zeng, Thomas; Senz, Janine; McConechy, Melissa K.; Anglesio, Michael S.; Kalloger, Steve E.; Yang, Winnie; Heravi-Moussavi, Alireza; Giuliany, Ryan; Chow, Christine; Fee, John; Zayed, Abdalnasser; Prentice, Leah; Melnyk, Nataliya; Turashvili, Gulisa; Delaney, Allen D.; Madore, Jason; Yip, Stephen; McPherson, Andrew W.; Ha, Gavin; Bell, Lynda; Fereday, Sian; Tam, Angela; Galletta, Laura; Tonin, Patricia N.; Provencher, Diane; Miller, Dianne; Jones, Steven J.M.; Moore, Richard A.; Morin, Gregg B.; Oloumi, Arusha; Boyd, Niki; Aparicio, Samuel A.; Shih, Ie-Ming; Mes-Masson, Anne-Marie; Bowtell, David D.; Hirst, Martin; Gilks, Blake; Marra, Marco A.; Huntsman, David G. (14 October 2010). "ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas". New England Journal of Medicine. 363 (16): 1532–1543. doi:10.1056/NEJMoa1008433. PMC 2976679. PMID 20942669.
  53. ^ Kelso, Timothy W R; Porter, Devin K; Amaral, Maria Luisa; Shokhirev, Maxim N; Benner, Christopher; Hargreaves, Diana C (2 October 2017). "Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers". eLife. 6 e30506. doi:10.7554/eLife.30506. PMC 5643100. PMID 28967863.
  54. ^ a b Mandal, Jayaprakash; Mandal, Prativa; Wang, Tian-Li; Shih, Ie-Ming (19 September 2022). "Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response". Journal of Biomedical Science. 29 (1) 71. doi:10.1186/s12929-022-00856-5. PMC 9484255. PMID 36123603.
  55. ^ Rago, Florencia; Rodrigues, Lindsey Ulkus; Bonney, Megan; Sprouffske, Kathleen; Kurth, Esther; Elliott, GiNell; Ambrose, Jessi; Aspesi, Peter; Oborski, Justin; Chen, Julie T.; McDonald, E. Robert; Mapa, Felipa A.; Ruddy, David A.; Kauffmann, Audrey; Abrams, Tinya; Bhang, Hyo-eun C.; Jagani, Zainab (1 March 2022). "Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia". Molecular Cancer Research. 20 (3): 361–372. doi:10.1158/1541-7786.MCR-21-0390. PMID 34799403.
  56. ^ Lee, Ryan S.; Roberts, Charles W. M. (March 2013). "Rhabdoid Tumors: An Initial Clue to the Role of Chromatin Remodeling in Cancer". Brain Pathology. 23 (2): 200–205. doi:10.1111/bpa.12021. PMC 8029057. PMID 23432645.
  57. ^ Versteege, Isabella; Sévenet, Nicolas; Lange, Julian; Rousseau-Merck, Marie-Françoise; Ambros, Peter; Handgretinger, Rupert; Aurias, Alain; Delattre, Olivier (July 1998). "Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer". Nature. 394 (6689): 203–206. Bibcode:1998Natur.394..203V. doi:10.1038/28212. PMID 9671307.
  58. ^ Errico, Alessia (June 13, 2014). "SMARCA4 mutated in SCCOHT". Nature Reviews Clinical Oncology. 11 (6): 302. doi:10.1038/nrclinonc.2014.63. PMID 24732945 – via www.nature.com.
  59. ^ Carril-Ajuria, Lucía; Santos, María; Roldán-Romero, Juan María; Rodriguez-Antona, Cristina; de Velasco, Guillermo (19 December 2019). "Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma". Cancers. 12 (1): 16. doi:10.3390/cancers12010016. PMC 7016957. PMID 31861590.
  60. ^ Varela, Ignacio; Tarpey, Patrick; Raine, Keiran; Huang, Dachuan; Ong, Choon Kiat; Stephens, Philip; Davies, Helen; Jones, David; Lin, Meng-Lay; Teague, Jon; Bignell, Graham; Butler, Adam; Cho, Juok; Dalgliesh, Gillian L.; Galappaththige, Danushka; Greenman, Chris; Hardy, Claire; Jia, Mingming; Latimer, Calli; Lau, King Wai; Marshall, John; McLaren, Stuart; Menzies, Andrew; Mudie, Laura; Stebbings, Lucy; Largaespada, David A.; Wessels, L. F. A.; Richard, Stephane; Kahnoski, Richard J.; Anema, John; A.Tuveson, David; Perez-Mancera, Pedro A.; Mustonen, Ville; Fischer, Andrej; Adams, David J.; Rust, Alistair; Chan-on, Waraporn; Subimerb, Chutima; Dykema, Karl; Furge, Kyle; Campbell, Peter J.; Teh, Bin Tean; Stratton, Michael R.; Futreal, P. Andrew (27 January 2011). "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma". Nature. 469 (7331): 539–542. Bibcode:2011Natur.469..539V. doi:10.1038/nature09639. PMC 3030920. PMID 21248752.
  61. ^ Li, Meng; Zhao, Hong; Zhang, Xiaosong; Wood, Laura D; Anders, Robert A; Choti, Michael A; Pawlik, Timothy M; Daniel, Hubert D; Kannangai, Rajesh; Offerhaus, G Johan A; Velculescu, Victor E; Wang, Linfang; Zhou, Shibin; Vogelstein, Bert; Hruban, Ralph H; Papadopoulos, Nick; Cai, Jianqiang; Torbenson, Michael S; Kinzler, Kenneth W (September 2011). "Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma". Nature Genetics. 43 (9): 828–829. doi:10.1038/ng.903. PMC 3163746. PMID 21822264.
  62. ^ Loesch, Robin; Chenane, Linda; Colnot, Sabine (23 September 2020). "ARID2 Chromatin Remodeler in Hepatocellular Carcinoma". Cells. 9 (10): 2152. doi:10.3390/cells9102152. PMC 7598172. PMID 32977645.
  63. ^ Wieczorek, Dagmar; Bögershausen, Nina; Beleggia, Filippo; Steiner-Haldenstätt, Sabine; Pohl, Esther; Li, Yun; Milz, Esther; Martin, Marcel; Thiele, Holger; Altmüller, Janine; Alanay, Yasemin; Kayserili, Hülya; Klein-Hitpass, Ludger; Böhringer, Stefan; Wollstein, Andreas; Albrecht, Beate; Boduroglu, Koray; Caliebe, Almuth; Chrzanowska, Krystyna; Cogulu, Ozgur; Cristofoli, Francesca; Czeschik, Johanna Christina; Devriendt, Koenraad; Dotti, Maria Teresa; Elcioglu, Nursel; Gener, Blanca; Goecke, Timm O.; Krajewska-Walasek, Małgorzata; Guillén-Navarro, Encarnación; Hayek, Joussef; Houge, Gunnar; Kilic, Esra; Simsek-Kiper, Pelin Özlem; López-González, Vanesa; Kuechler, Alma; Lyonnet, Stanislas; Mari, Francesca; Marozza, Annabella; Mathieu Dramard, Michèle; Mikat, Barbara; Morin, Gilles; Morice-Picard, Fanny; Özkinay, Ferda; Rauch, Anita; Renieri, Alessandra; Tinschert, Sigrid; Utine, G. Eda; Vilain, Catheline; Vivarelli, Rossella; Zweier, Christiane; Nürnberg, Peter; Rahmann, Sven; Vermeesch, Joris; Lüdecke, Hermann-Josef; Zeschnigk, Michael; Wollnik, Bernd (20 December 2013). "A comprehensive molecular study on Coffin–Siris and Nicolaides–Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling". Human Molecular Genetics. 22 (25): 5121–5135. doi:10.1093/hmg/ddt366. hdl:11365/44765. PMID 23906836.
  64. ^ Santen, Gijs W.E.; Aten, Emmelien; Vulto-van Silfhout, Anneke T.; Pottinger, Caroline; van Bon, Bregje W.M.; van Minderhout, Ivonne J.H.M.; Snowdowne, Ronelle; van der Lans, Christian A.C.; Boogaard, Merel; Linssen, Margot M.L.; Vijfhuizen, Linda; van der Wielen, Michiel J.R.; Vollebregt, M.J. Ellen; Breuning, Martijn H.; Kriek, Marjolein; van Haeringen, Arie; den Dunnen, Johan T.; Hoischen, Alexander; Clayton-Smith, Jill; de Vries, Bert B.A.; Hennekam, Raoul C.M.; van Belzen, Martine J.; Almureikhi, Mariam; Baban, Anwar; Barbosa, Mafalda; Ben-Omran, Tawfeg; Berry, Katherine; Bigoni, Stefania; Boute, Odile; Brueton, Louise; van der Burgt, Ineke; Canham, Natalie; Chandler, Kate E.; Chrzanowska, Krystyna; Collins, Amanda L.; de Toni, Teresa; Dean, John; den Hollander, Nicolette S.; Flore, Leigh Anne; Fryer, Alan; Gardham, Alice; Graham, John M.; Harrison, Victoria; Horn, Denise; Jongmans, Marjolijn C.; Josifova, Dragana; Kant, Sarina G.; Kapoor, Seema; Kingston, Helen; Kini, Usha; Kleefstra, Tjitske; Krajewska-Walasek, Małgorzata; Kramer, Nancy; Maas, Saskia M.; Maciel, Patricia; Mancini, Grazia M.S.; Maystadt, Isabelle; McKee, Shane; Milunsky, Jeff M.; Nampoothiri, Sheela; Newbury-Ecob, Ruth; Nikkel, Sarah M.; Parker, Michael J.; Pérez-Jurado, Luis A.; Robertson, Stephen P.; Rooryck, Caroline; Shears, Debbie; Silengo, Margherita; Singh, Ankur; Smigiel, Robert; Soares, Gabriela; Splitt, Miranda; Stewart, Helen; Sweeney, Elizabeth; Tassabehji, May; Tuysuz, Beyhan; van Eerde, Albertien M.; Vincent-Delorme, Catherine; Wilson, Louise C.; Yesil, Gozde (November 2013). "Coffin-Siris Syndrome and the BAF Complex: Genotype-Phenotype Study in 63 Patients". Human Mutation. 34 (11): 1519–1528. doi:10.1002/humu.22394. PMID 23929686.
  65. ^ Tsurusaki, Yoshinori; Okamoto, Nobuhiko; Ohashi, Hirofumi; Kosho, Tomoki; Imai, Yoko; Hibi-Ko, Yumiko; Kaname, Tadashi; Naritomi, Kenji; Kawame, Hiroshi; Wakui, Keiko; Fukushima, Yoshimitsu; Homma, Tomomi; Kato, Mitsuhiro; Hiraki, Yoko; Yamagata, Takanori; Yano, Shoji; Mizuno, Seiji; Sakazume, Satoru; Ishii, Takuma; Nagai, Toshiro; Shiina, Masaaki; Ogata, Kazuhiro; Ohta, Tohru; Niikawa, Norio; Miyatake, Satoko; Okada, Ippei; Mizuguchi, Takeshi; Doi, Hiroshi; Saitsu, Hirotomo; Miyake, Noriko; Matsumoto, Naomichi (April 2012). "Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome". Nature Genetics. 44 (4): 376–378. doi:10.1038/ng.2219. PMID 22426308.
  66. ^ Van Houdt, Jeroen K J; Nowakowska, Beata Anna; Sousa, Sérgio B; van Schaik, Barbera D C; Seuntjens, Eve; Avonce, Nelson; Sifrim, Alejandro; Abdul-Rahman, Omar A; van den Boogaard, Marie-José H; Bottani, Armand; Castori, Marco; Cormier-Daire, Valérie; Deardorff, Matthew A; Filges, Isabel; Fryer, Alan; Fryns, Jean-Pierre; Gana, Simone; Garavelli, Livia; Gillessen-Kaesbach, Gabriele; Hall, Bryan D; Horn, Denise; Huylebroeck, Danny; Klapecki, Jakub; Krajewska-Walasek, Malgorzata; Kuechler, Alma; Lines, Matthew A; Maas, Saskia; MacDermot, Kay D; McKee, Shane; Magee, Alex; de Man, Stella A; Moreau, Yves; Morice-Picard, Fanny; Obersztyn, Ewa; Pilch, Jacek; Rosser, Elizabeth; Shannon, Nora; Stolte-Dijkstra, Irene; Van Dijck, Patrick; Vilain, Catheline; Vogels, Annick; Wakeling, Emma; Wieczorek, Dagmar; Wilson, Louise; Zuffardi, Orsetta; van Kampen, Antoine H C; Devriendt, Koenraad; Hennekam, Raoul; Vermeesch, Joris Robert (April 2012). "Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome". Nature Genetics. 44 (4): 445–449. doi:10.1038/ng.1105. PMID 22366787.
  67. ^ Sousa, Sérgio B.; Hennekam, Raoul C. (September 2014). "Phenotype and genotype in Nicolaides–Baraitser syndrome". American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 166 (3): 302–314. doi:10.1002/ajmg.c.31409. PMID 25169058.
  68. ^ Takeda, Takashi; Banno, Kouji; Okawa, Ryuichiro; Yanokura, Megumi; Iijima, Moito; Irie-Kunitomi, Haruko; Nakamura, Kanako; Iida, Miho; Adachi, Masataka; Umene, Kiyoko; Nogami, Yuya; Masuda, Kenta; Kobayashi, Yusuke; Tominaga, Eiichiro; Aoki, Daisuke (February 2016). "ARID1A gene mutation in ovarian and endometrial cancers (Review)". Oncology Reports. 35 (2): 607–613. doi:10.3892/or.2015.4421. PMC 4689482. PMID 26572704.
  69. ^ Mathur, Radhika; Alver, Burak H; San Roman, Adrianna K; Wilson, Boris G; Wang, Xiaofeng; Agoston, Agoston T; Park, Peter J; Shivdasani, Ramesh A; Roberts, Charles W M (February 2017). "ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice". Nature Genetics. 49 (2): 296–302. doi:10.1038/ng.3744. PMC 5285448. PMID 27941798.
  70. ^ a b c Chandler, Ronald L.; Damrauer, Jeffrey S.; Raab, Jesse R.; Schisler, Jonathan C.; Wilkerson, Matthew D.; Didion, John P.; Starmer, Joshua; Serber, Daniel; Yee, Della; Xiong, Jessie; Darr, David B.; de Villena, Fernando Pardo-Manuel; Kim, William Y.; Magnuson, Terry (27 January 2015). "Coexistent ARID1A–PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling". Nature Communications. 6 (1) 6118. Bibcode:2015NatCo...6.6118C. doi:10.1038/ncomms7118. PMC 4308813. PMID 25625625.
  71. ^ Kim, Minchul; Lu, Falong; Zhang, Yi (September 2016). "Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer". Cell Reports. 17 (1): 275–288. doi:10.1016/j.celrep.2016.09.003. PMC 7734570. PMID 27681437.
  72. ^ a b c Bitler, Benjamin G; Aird, Katherine M; Garipov, Azat; Li, Hua; Amatangelo, Michael; Kossenkov, Andrew V; Schultz, David C; Liu, Qin; Shih, Ie-Ming; Conejo-Garcia, Jose R; Speicher, David W; Zhang, Rugang (March 2015). "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers". Nature Medicine. 21 (3): 231–238. doi:10.1038/nm.3799. PMC 4352133. PMID 25686104.
  73. ^ Watson, Pamela M.; DeVaux, Chelsea A.; Freeman, Kevin W. (13 March 2025). "Loss of ARID1A leads to a cold tumor phenotype via suppression of IFNγ signaling". Scientific Reports. 15 (1) 8716. Bibcode:2025NatSR..15.8716W. doi:10.1038/s41598-025-91688-4. PMC 11906763. PMID 40082458.
  74. ^ Li, Jing; Wang, Weichao; Zhang, Yajia; Cieślik, Marcin; Guo, Jipeng; Tan, Mengyao; Green, Michael D.; Wang, Weimin; Lin, Heng; Li, Wei; Wei, Shuang; Zhou, Jiajia; Li, Gaopeng; Jing, Xiaojun; Vatan, Linda; Zhao, Lili; Bitler, Benjamin; Zhang, Rugang; Cho, Kathleen R.; Dou, Yali; Kryczek, Ilona; Chan, Timothy A.; Huntsman, David; Chinnaiyan, Arul M.; Zou, Weiping (20 April 2020). "Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy". Journal of Clinical Investigation. 130 (5): 2712–2726. doi:10.1172/JCI134402. PMC 7190935. PMID 32027624.
  75. ^ a b Li, Ni; Liu, Qiuli; Han, Ying; Pei, Siyu; Cheng, Bisheng; Xu, Junyu; Miao, Xiang; Pan, Qiang; Wang, Hanling; Guo, Jiacheng; Wang, Xuege; Zhang, Guoying; Lian, Yannan; Zhang, Wei; Zang, Yi; Tan, Minjia; Li, Qintong; Wang, Xiaoming; Xiao, Yichuan; Hu, Guohong; Jiang, Jun; Huang, Hai; Qin, Jun (26 November 2022). "ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression". Nature Communications. 13 (1) 7281. Bibcode:2022NatCo..13.7281L. doi:10.1038/s41467-022-34871-9. PMC 9701216. PMID 36435834.
  76. ^ a b c Wang, Xiaofeng; Wang, Su; Troisi, Emma C.; Howard, Thomas P.; Haswell, Jeffrey R.; Wolf, Bennett K.; Hawk, William H.; Ramos, Pilar; Oberlick, Elaine M.; Tzvetkov, Evgeni P.; Ross, Aaron; Vazquez, Francisca; Hahn, William C.; Park, Peter J.; Roberts, Charles W. M. (23 April 2019). "BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors". Nature Communications. 10 (1) 1881. Bibcode:2019NatCo..10.1881W. doi:10.1038/s41467-019-09891-7. PMC 6479050. PMID 31015438.
  77. ^ Nakayama, Robert T; Pulice, John L; Valencia, Alfredo M; McBride, Matthew J; McKenzie, Zachary M; Gillespie, Mark A; Ku, Wai Lim; Teng, Mingxiang; Cui, Kairong; Williams, Robert T; Cassel, Seth H; Qing, He; Widmer, Christian J; Demetri, George D; Irizarry, Rafael A; Zhao, Keji; Ranish, Jeffrey A; Kadoch, Cigall (November 2017). "SMARCB1 is required for widespread BAF complex–mediated activation of enhancers and bivalent promoters". Nature Genetics. 49 (11): 1613–1623. doi:10.1038/ng.3958. PMC 5803080. PMID 28945250.
  78. ^ Erkek, Serap; Johann, Pascal D.; Finetti, Martina A.; Drosos, Yiannis; Chou, Hsien-Chao; Zapatka, Marc; Sturm, Dominik; Jones, David T.W.; Korshunov, Andrey; Rhyzova, Marina; Wolf, Stephan; Mallm, Jan-Philipp; Beck, Katja; Witt, Olaf; Kulozik, Andreas E.; Frühwald, Michael C.; Northcott, Paul A.; Korbel, Jan O.; Lichter, Peter; Eils, Roland; Gajjar, Amar; Roberts, Charles W.M.; Williamson, Daniel; Hasselblatt, Martin; Chavez, Lukas; Pfister, Stefan M.; Kool, Marcel (January 2019). "Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation". Cancer Cell. 35 (1): 95–110.e8. doi:10.1016/j.ccell.2018.11.014. PMC 6341227. PMID 30595504.
  79. ^ Klein, Ulf; Tu, Yuhai; Stolovitzky, Gustavo A.; Keller, Jeffrey L.; Haddad, Joseph; Miljkovic, Vladan; Cattoretti, Giorgio; Califano, Andrea; Dalla-Favera, Riccardo (4 March 2003). "Transcriptional analysis of the B cell germinal center reaction". Proceedings of the National Academy of Sciences. 100 (5): 2639–2644. Bibcode:2003PNAS..100.2639K. doi:10.1073/pnas.0437996100. PMC 151393. PMID 12604779.
  80. ^ Vitte, Jeremie; Gao, Fuying; Coppola, Giovanni; Judkins, Alexander R.; Giovannini, Marco (21 August 2017). "Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development". Nature Communications. 8 (1) 300. Bibcode:2017NatCo...8..300V. doi:10.1038/s41467-017-00346-5. PMC 5563506. PMID 28824165.
  81. ^ Graf, Monika; Interlandi, Marta; Moreno, Natalia; Holdhof, Dörthe; Göbel, Carolin; Melcher, Viktoria; Mertins, Julius; Albert, Thomas K.; Kastrati, Dennis; Alfert, Amelie; Holsten, Till; de Faria, Flavia; Meisterernst, Michael; Rossig, Claudia; Warmuth-Metz, Monika; Nowak, Johannes; Meyer zu Hörste, Gerd; Mayère, Chloe; Nef, Serge; Johann, Pascal; Frühwald, Michael C.; Dugas, Martin; Schüller, Ulrich; Kerl, Kornelius (22 March 2022). "Single-cell transcriptomics identifies potential cells of origin of MYC rhabdoid tumors". Nature Communications. 13 (1) 1544. Bibcode:2022NatCo..13.1544G. doi:10.1038/s41467-022-29152-4. PMC 8941154. PMID 35318328.
  82. ^ Alfert, Amelie; Walter, Carolin; Moreno, Natalia; Melcher, Viktoria; Graf, Monika; Hotfilder, Marc; Dugas, Martin; Albert, Thomas; Kerl, Kornelius (15 April 2022). "Smarcb1 Loss Results in a Deregulation of esBAF Binding and Impacts the Expression of Neurodevelopmental Genes". Cells. 11 (8): 1354. doi:10.3390/cells11081354. PMC 9027123. PMID 35456033.
  83. ^ Knutson, Sarah K.; Warholic, Natalie M.; Wigle, Tim J.; Klaus, Christine R.; Allain, Christina J.; Raimondi, Alejandra; Porter Scott, Margaret; Chesworth, Richard; Moyer, Mikel P.; Copeland, Robert A.; Richon, Victoria M.; Pollock, Roy M.; Kuntz, Kevin W.; Keilhack, Heike (7 May 2013). "Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2". Proceedings of the National Academy of Sciences. 110 (19): 7922–7927. Bibcode:2013PNAS..110.7922K. doi:10.1073/pnas.1303800110. PMC 3651445. PMID 23620515.
  84. ^ Kurmasheva, Raushan T.; Erickson, Stephen W.; Earley, Eric; Smith, Malcolm A.; Houghton, Peter J. (February 2021). "In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium". Pediatric Blood & Cancer. 68 (2) e28772. doi:10.1002/pbc.28772. PMC 10276573. PMID 33089597.
  85. ^ Vande Walle, Lieselotte; Van Opdenbosch, Nina; Jacques, Peggy; Fossoul, Amelie; Verheugen, Eveline; Vogel, Peter; Beyaert, Rudi; Elewaut, Dirk; Kanneganti, Thirumala-Devi; van Loo, Geert; Lamkanfi, Mohamed (August 2014). "Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis". Nature. 512 (7512): 69–73. Bibcode:2014Natur.512...69W. doi:10.1038/nature13322. PMC 4126806. PMID 25043000.
  86. ^ Holdhof, Dörthe; Johann, Pascal D.; Spohn, Michael; Bockmayr, Michael; Safaei, Sepehr; Joshi, Piyush; Masliah-Planchon, Julien; Ho, Ben; Andrianteranagna, Mamy; Bourdeaut, Franck; Huang, Annie; Kool, Marcel; Upadhyaya, Santhosh A.; Bendel, Anne E.; Indenbirken, Daniela; Foulkes, William D.; Bush, Jonathan W.; Creytens, David; Kordes, Uwe; Frühwald, Michael C.; Hasselblatt, Martin; Schüller, Ulrich (February 2021). "Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases". Acta Neuropathologica. 141 (2): 291–301. doi:10.1007/s00401-020-02250-7. PMC 7847432. PMID 33331994.
  87. ^ a b Jelinic, Petar; Mueller, Jennifer J; Olvera, Narciso; Dao, Fanny; Scott, Sasinya N; Shah, Ronak; Gao, JianJiong; Schultz, Nikolaus; Gonen, Mithat; Soslow, Robert A; Berger, Michael F; Levine, Douglas A (May 2014). "Recurrent SMARCA4 mutations in small cell carcinoma of the ovary". Nature Genetics. 46 (5): 424–426. doi:10.1038/ng.2922. PMC 5699446. PMID 24658004.
  88. ^ Duan, Huanli; Gao, Wei; Wang, Leiming; Cao, Feng; Teng, Lianghong (December 2021). "Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review". Diagnostic Pathology. 16 (1) 30. doi:10.1186/s13000-021-01091-6. PMC 8033741. PMID 33836796.
  89. ^ Tischkowitz, Marc; Huang, Sidong; Banerjee, Susana; Hague, Jennifer; Hendricks, William P.D.; Huntsman, David G.; Lang, Jessica D.; Orlando, Krystal A.; Oza, Amit M.; Pautier, Patricia; Ray-Coquard, Isabelle; Trent, Jeffrey M.; Witcher, Michael; Witkowski, Leora; McCluggage, W. Glenn; Levine, Douglas A.; Foulkes, William D.; Weissman, Bernard E. (1 August 2020). "Small-Cell Carcinoma of the Ovary, Hypercalcemic Type–Genetics, New Treatment Targets, and Current Management Guidelines". Clinical Cancer Research. 26 (15): 3908–3917. doi:10.1158/1078-0432.CCR-19-3797. PMC 7415570. PMID 32156746.
  90. ^ Wilson, Boris G.; Helming, Katherine C.; Wang, Xiaofeng; Kim, Youngha; Vazquez, Francisca; Jagani, Zainab; Hahn, William C.; Roberts, Charles W. M. (1 March 2014). "Residual Complexes Containing SMARCA2 (BRM) Underlie the Oncogenic Drive of SMARCA4 ( BRG1 ) Mutation". Molecular and Cellular Biology. 34 (6): 1136–1144. doi:10.1128/MCB.01372-13. PMC 3958034. PMID 24421395.
  91. ^ Longo, Vito; Catino, Annamaria; Montrone, Michele; Montagna, Elisabetta Sara; Pesola, Francesco; Marech, Ilaria; Pizzutilo, Pamela; Nardone, Annalisa; Perrone, Antonella; Gesualdo, Monica; Galetta, Domenico (13 March 2024). "Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go". International Journal of Molecular Sciences. 25 (6): 3237. doi:10.3390/ijms25063237. PMC 10970296. PMID 38542211.
  92. ^ Bhat-Nakshatri, Poornima; Khatpe, Aditi S.; Chen, Duojiao; Batic, Katie; Mang, Henry; Herodotou, Christopher; McGuire, Patrick C.; Xuei, Xiaoling; Erdogan, Cihat; Gao, Hongyu; Liu, Yunlong; Sandusky, George; Storniolo, Anna Maria; Nakshatri, Harikrishna (5 January 2024). "Signaling Pathway Alterations Driven by BRCA1 and BRCA2 Germline Mutations are Sufficient to Initiate Breast Tumorigenesis by the PIK3CAH1047R Oncogene". Cancer Research Communications. 4 (1): 38–54. doi:10.1158/2767-9764.CRC-23-0330. PMC 10774565. PMID 38059556.
  93. ^ Bochar, Daniel A; Wang, Lai; Beniya, Hideo; Kinev, Alexander; Xue, Yutong; Lane, William S; Wang, Weidong; Kashanchi, Fatah; Shiekhattar, Ramin (July 2000). "BRCA1 Is Associated with a Human SWI/SNF-Related Complex". Cell. 102 (2): 257–265. doi:10.1016/S0092-8674(00)00030-1. PMID 10943845.
  94. ^ Orvis, Tess; Hepperla, Austin; Walter, Vonn; Song, Shujie; Simon, Jeremy; Parker, Joel; Wilkerson, Matthew D.; Desai, Nisarg; Major, Michael B.; Hayes, D. Neil; Davis, Ian J.; Weissman, Bernard (15 November 2014). "BRG1/SMARCA4 Inactivation Promotes Non–Small Cell Lung Cancer Aggressiveness by Altering Chromatin Organization". Cancer Research. 74 (22): 6486–6498. doi:10.1158/0008-5472.CAN-14-0061. PMC 4233181. PMID 25115300.
  95. ^ Concepcion, Carla P.; Ma, Sai; LaFave, Lindsay M.; Bhutkar, Arjun; Liu, Manyuan; DeAngelo, Lydia P.; Kim, Jonathan Y.; Del Priore, Isabella; Schoenfeld, Adam J.; Miller, Manon; Kartha, Vinay K.; Westcott, Peter M.K.; Sánchez-Rivera, Francisco J.; Meli, Kevin; Gupta, Manav; Bronson, Roderick T.; Riely, Gregory J.; Rekhtman, Natasha; Rudin, Charles M.; Kim, Carla F.; Regev, Aviv; Buenrostro, Jason D.; Jacks, Tyler (1 February 2022). "Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung". Cancer Discovery. 12 (2): 562–585. doi:10.1158/2159-8290.CD-21-0248. PMC 8831463. PMID 34561242.
  96. ^ Shi, X; Wang, Q; Gu, J; Xuan, Z; Wu, J I (3 November 2016). "SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development". Oncogene. 35 (44): 5746–5758. doi:10.1038/onc.2016.108. PMID 27065321.
  97. ^ Kurashima, Kiminori; Kashiwagi, Hideto; Shimomura, Iwao; Suzuki, Ayako; Takeshita, Fumitaka; Mazevet, Marianne; Harata, Masahiko; Yamashita, Takayuki; Yamamoto, Yusuke; Kohno, Takashi; Shiotani, Bunsyo (1 June 2020). "SMARCA4 deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma". NAR Cancer. 2 (2) zcaa005. doi:10.1093/narcan/zcaa005. PMC 8210217. PMID 34316685.
  98. ^ Zhang, Xuewei; Zhang, Yixuan; Zhao, Jinyi; Wu, Yinjie; Zhang, Na; Shen, Wenjing (27 May 2023). "ARID1A mutations in cancer development: mechanism and therapy". Carcinogenesis. 44 (3): 197–208. doi:10.1093/carcin/bgad011. PMID 36882165.
  99. ^ Xu, Shouying; Tang, Chao (4 October 2021). "The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?". Frontiers in Oncology. 11 745187. doi:10.3389/fonc.2021.745187. PMC 8521028. PMID 34671561.
  100. ^ Alldredge, Jill K.; Eskander, Ramez N. (December 2017). "EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers". Gynecologic Oncology Research and Practice. 4 (1) 17. doi:10.1186/s40661-017-0052-y. PMC 5663065. PMID 29093822.
  101. ^ Shen, Jianfeng; Peng, Yang; Wei, Leizhen; Zhang, Wei; Yang, Lin; Lan, Li; Kapoor, Prabodh; Ju, Zhenlin; Mo, Qianxing; Shih, Ie-Ming; Uray, Ivan P.; Wu, Xiangwei; Brown, Powel H.; Shen, Xuetong; Mills, Gordon B.; Peng, Guang (1 July 2015). "ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors". Cancer Discovery. 5 (7): 752–767. doi:10.1158/2159-8290.CD-14-0849. PMC 4497871. PMID 26069190.
  102. ^ Williamson, Chris T.; Miller, Rowan; Pemberton, Helen N.; Jones, Samuel E.; Campbell, James; Konde, Asha; Badham, Nicholas; Rafiq, Rumana; Brough, Rachel; Gulati, Aditi; Ryan, Colm J.; Francis, Jeff; Vermulen, Peter B.; Reynolds, Andrew R.; Reaper, Philip M.; Pollard, John R.; Ashworth, Alan; Lord, Christopher J. (13 December 2016). "ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A". Nature Communications. 7 (1) 13837. Bibcode:2016NatCo...713837W. doi:10.1038/ncomms13837. PMC 5159945. PMID 27958275.
  103. ^ Wu, Changjie; Lyu, Junfang; Yang, Eun Ju; Liu, Yifan; Zhang, Baoyuan; Shim, Joong Sup (10 August 2018). "Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells". Nature Communications. 9 (1) 3212. Bibcode:2018NatCo...9.3212W. doi:10.1038/s41467-018-05694-4. PMC 6086874. PMID 30097580.
  104. ^ Yakovlev, Vasily A.; Sullivan, Stephanie A.; Fields, Emma C.; Temkin, Sarah M. (22 February 2023). "PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality". Frontiers in Oncology. 13 1124147. doi:10.3389/fonc.2023.1124147. PMC 9992988. PMID 36910637.
  105. ^ Kearns, Bridger; McKell, Andralyn; Steveson, Isaac; Worley, Peyton; Barton, Braeden; Bennett, Jordan; Anderson, DeLaney; Harris, Jacob; Christensen, James; Barrott, Jared J. (13 May 2025). "ARID1A and Its Impact Across the Hallmarks of Cancer". International Journal of Molecular Sciences. 26 (10): 4644. doi:10.3390/ijms26104644. PMC 12111594. PMID 40429787.
  106. ^ Wu, Shuai; Fukumoto, Takeshi; Lin, Jianhuang; Nacarelli, Timothy; Wang, Yemin; Ong, Dionzie; Liu, Heng; Fatkhutdinov, Nail; Zundell, Joseph A.; Karakashev, Sergey; Zhou, Wei; Schwartz, Lauren E.; Tang, Hsin-Yao; Drapkin, Ronny; Liu, Qin; Huntsman, David G.; Kossenkov, Andrew V.; Speicher, David W.; Schug, Zachary T.; Van Dang, Chi; Zhang, Rugang (11 January 2021). "Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma". Nature Cancer. 2 (2): 189–200. doi:10.1038/s43018-020-00160-x. PMC 8168620. PMID 34085048.
  107. ^ Kazansky, Yaniv; Cameron, Daniel; Mueller, Helen S.; Demarest, Phillip; Zaffaroni, Nadia; Arrighetti, Noemi; Zuco, Valentina; Kuwahara, Yasumichi; Somwar, Romel; Ladanyi, Marc; Qu, Rui; de Stanchina, Elisa; Dela Cruz, Filemon S.; Kung, Andrew L.; Gounder, Mrinal M.; Kentsis, Alex (3 June 2024). "Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination Therapy". Cancer Discovery. 14 (6): 965–981. doi:10.1158/2159-8290.CD-23-0110. PMC 11147720. PMID 38315003.
  108. ^ Gounder, Mrinal; Schöffski, Patrick; Jones, Robin L; Agulnik, Mark; Cote, Gregory M; Villalobos, Victor M; Attia, Steven; Chugh, Rashmi; Chen, Tom Wei-Wu; Jahan, Thierry; Loggers, Elizabeth T; Gupta, Abha; Italiano, Antoine; Demetri, George D; Ratan, Ravin; Davis, Lara E; Mir, Olivier; Dileo, Palma; Van Tine, Brian A; Pressey, Joseph G; Lingaraj, Trupti; Rajarethinam, Anand; Sierra, Laura; Agarwal, Shefali; Stacchiotti, Silvia (November 2020). "Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study". The Lancet Oncology. 21 (11): 1423–1432. doi:10.1016/S1470-2045(20)30451-4. PMID 33035459.
  109. ^ Miao, Diana; Margolis, Claire A.; Gao, Wenhua; Voss, Martin H.; Li, Wei; Martini, Dylan J.; Norton, Craig; Bossé, Dominick; Wankowicz, Stephanie M.; Cullen, Dana; Horak, Christine; Wind-Rotolo, Megan; Tracy, Adam; Giannakis, Marios; Hodi, Frank Stephen; Drake, Charles G.; Ball, Mark W.; Allaf, Mohamad E.; Snyder, Alexandra; Hellmann, Matthew D.; Ho, Thai; Motzer, Robert J.; Signoretti, Sabina; Kaelin, William G.; Choueiri, Toni K.; Van Allen, Eliezer M. (16 February 2018). "Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma". Science. 359 (6377): 801–806. Bibcode:2018Sci...359..801M. doi:10.1126/science.aan5951. PMC 6035749. PMID 29301960.
  110. ^ Stern, Michael; Jensen, Robert; Herskowitz, Ira (October 1984). "Five SWI genes are required for expression of the HO gene in yeast". Journal of Molecular Biology. 178 (4): 853–868. doi:10.1016/0022-2836(84)90315-2. PMID 6436497.
  111. ^ Neigeborn, Lenore; Carlson, Marian (1 December 1984). "GENES AFFECTING THE REGULATION OF SUC2 GENE EXPRESSION BY GLUCOSE REPRESSION IN SACCHAROMYCES CEREVISIAE". Genetics. 108 (4): 845–858. doi:10.1093/genetics/108.4.845. PMC 1224269. PMID 6392017.
  112. ^ Martens, Joseph A.; Winston, Fred (1 September 2002). "Evidence that Swi/Snf directly represses transcription in S. cerevisiae". Genes & Development. 16 (17): 2231–2236. doi:10.1101/gad.1009902. PMC 186664.
  113. ^ Hirschhorn, J N; Brown, S A; Clark, C D; Winston, F (1 December 1992). "Evidence that SNF2/SWI2 and SNF5 activate transcription in yeast by altering chromatin structure". Genes & Development. 6 (12a): 2288–2298. doi:10.1101/gad.6.12a.2288. PMID 1459453.
  114. ^ Cairns, B R; Kim, Y J; Sayre, M H; Laurent, B C; Kornberg, R D (March 1994). "A multisubunit complex containing the SWI1/ADR6,SWI2/SNF2, SWI3, SNF5, and SNF6 gene products isolated fromyeast". Proceedings of the National Academy of Sciences. 91 (5): 1950–1954. Bibcode:1994PNAS...91.1950C. doi:10.1073/pnas.91.5.1950. PMC 43282. PMID 8127913.
  115. ^ Tamkun, John W.; Deuring, Renate; Scott, Matthew P.; Kissinger, Mark; Pattatucci, Angela M.; Kaufman, Thomas C.; Kennison, James A. (February 1992). "brahma: A regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2SWI2". Cell. 68 (3): 561–572. doi:10.1016/0092-8674(92)90191-E. PMID 1346755.
  116. ^ Kennison, J A; Tamkun, J W (November 1988). "Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila". Proceedings of the National Academy of Sciences. 85 (21): 8136–8140. Bibcode:1988PNAS...85.8136K. doi:10.1073/pnas.85.21.8136. PMC 282375. PMID 3141923.
  117. ^ Terriente-Félix, Ana; de Celis, Jose F. (May 2009). "Osa, a subunit of the BAP chromatin-remodelling complex, participates in the regulation of gene expression in response to EGFR signalling in the Drosophila wing". Developmental Biology. 329 (2): 350–361. doi:10.1016/j.ydbio.2009.03.010. PMID 19306864.
  118. ^ Rendina, Rosaria; Strangi, Agostino; Avallone, Bice; Giordano, Ennio (1 September 2010). "Bap170, a Subunit of the Drosophila PBAP Chromatin Remodeling Complex, Negatively Regulates the EGFR Signaling". Genetics. 186 (1): 167–181. doi:10.1534/genetics.110.118695. PMC 2940285. PMID 20551433.
  119. ^ Molnar, Cristina; López-Varea, Ana; Hernández, Rosario; de Celis, Jose F (1 November 2006). "A Gain-of-Function Screen Identifying Genes Required for Vein Formation in the Drosophila melanogaster Wing". Genetics. 174 (3): 1635–1659. doi:10.1534/genetics.106.061283. PMC 1667087. PMID 16980395.
  120. ^ Muchardt, C.; Yaniv, M.; Mattei, M.-G. (April 1994). "Assignment of HBRM, the human homolog of S. cerevisiae SNF2/SWI2 and Drosophila brm genes, to chromosome region 9p23?p24, by in situ hybridization". Mammalian Genome. 5 (4): 241–243. doi:10.1007/BF00360554. PMID 8012116.
  121. ^ Muchardt, C.; Yaniv, M. (November 1993). "A human homologue of Saccharomyces cerevisiae SNF2/SWI2 and Drosophila brm genes potentiates transcriptional activation by the glucocorticoid receptor". The EMBO Journal. 12 (11): 4279–4290. doi:10.1002/j.1460-2075.1993.tb06112.x. PMC 413724. PMID 8223438.
  122. ^ Mani, Udayakumar; S., Alagu Sankareswaran; Goutham R. N., Arun; Mohan S., Suma (29 September 2017). "SWI/SNF Infobase—An exclusive information portal for SWI/SNF remodeling complex subunits". PLOS ONE. 12 (9) e0184445. Bibcode:2017PLoSO..1284445M. doi:10.1371/journal.pone.0184445. PMC 5621669. PMID 28961249.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.